Filled capsules awaiting aluminum plastic quality testing at a production line of Shijiazhuang Yiling Pharmaceutical. Photo: Courtesy of Shijiazhuang Yiling Pharmaceutical

 Chinese A-share listed pharmaceutical companies that have set up businesses in Ukraine in the past year have said that the current crisis is having little impact on their operations.

A member of staff at Shijiazhuang Yiling Pharmaceutical Co said that overseas sales revenue accounts for a low proportion of the company's total operating revenue, and Ukraine is only a small part of it. The current tension is having no impact on the company, thepaper.cn reported on Friday.

Chinese herbal medicine maker Yiling Pharmaceutical is well-known for its patented Lianhua Qingwen capsules that have been recommended for COVID-19 treatment.

On June 29, 2021, Yiling Pharmaceutical announced that it had received approval for registration of Lianhua Qingwen from the Ministry of Health of Ukraine. The company said it would help it to expand in overseas markets.

Shenzhen Kangtai Biological Products Co, which has conducted phase III clinical trials of its inactivated COVID-19 vaccine in Ukraine, said that the impact of the current situation in the country cannot yet be assessed, thepaper.cn reported.

But phase III clinical trials of the COVID-19 vaccine in other countries, such as Malaysia, are progressing normally, an employee of Kangtai Biological said.

On July 16, 2021, Kangtai Biological announced that its inactivated COVID-19 vaccine received approval from the Ukrainian Ministry of Health for phase III clinical trials. After the export of vaccine samples, the clinical field work will officially start, it said.